ReviewBMC medicine2012
New treatments for influenza.
Review in BMC medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 2 syntheses or guidelines pooled it, 95 citations in OpenAlex.
- The effect of probiotics on respiratory tract infection with special emphasis on COVID-19: Systemic review 2010-20.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021Pooled it
- Amantadine and rimantadine for influenza A in children and the elderly.The Cochrane database of systematic reviews · 2014Pooled it
- Impact of Infectious Disease afterNutrients · 2022Trial
- Article
- CRISPR-Based Assays for Point-of-Need Detection and Subtyping of Influenza.The Journal of molecular diagnostics : JMD · 2024Article
- Outlining recent updates on influenza therapeutics and vaccines: A comprehensive review.Vaccine: X · 2024Review
- Fasting mimicking diet in mice delays cancer growth and reduces immunotherapy-associated cardiovascular and systemic side effects.Nature communications · 2023Article
- Opportunistic etiological agents causing lung infections: emerging need to transform lung-targeted delivery.Heliyon · 2022Review
- An anti-influenza A virus microbial metabolite acts by degrading viral endonuclease PA.Nature communications · 2022Article
- Nanotechnology Integration for SARS-CoV-2 Diagnosis and Treatment: An Approach to Preventing Pandemic.Nanomaterials (Basel, Switzerland) · 2021Review
- Progression and Trends in Virus from Influenza A to COVID-19: An Overview of Recent Studies.Viruses · 2021Review
- The CRISPR revolution and its potential impact on global health security.Pathogens and global health · 2021Review
- Application of Nanotechnology in the COVID-19 Pandemic.International journal of nanomedicine · 2021Review
- Quercetin as a Natural Therapeutic Candidate for the Treatment of Influenza Virus.Biomolecules · 2020Review
- Artificial intelligence approach fighting COVID-19 with repurposing drugs.Biomedical journal · 2020Article
- Antiviral Activities of Compounds Isolated fromBiomolecules · 2020Article
- On Facing the SARS-CoV-2 (COVID-19) with Combination of Nanomaterials and Medicine: Possible Strategies and First Challenges.Nanomaterials (Basel, Switzerland) · 2020Review
- Discovery and characterization of a novel peptide inhibitor against influenza neuraminidase.RSC medicinal chemistry · 2020Article
- Influenza viruses that require 10 genomic segments as antiviral therapeutics.PLoS pathogens · 2019Article
- Development of effective anti-influenza drugs: congeners and conjugates - a review.Journal of biomedical science · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Influenza has a long history of causing morbidity and mortality in the human population through routine seasonal spread and global pandemics. The high mutation rate of the RNA genome of the influenza virus, combined with assortment of its multiple genomic segments, promote antigenic diversity and new subtypes, allowing the virus to evade vaccines and become resistant to antiviral drugs. There is thus a continuing need for new anti-influenza therapy using novel targets and creative strategies. In this review, we summarize prospective future therapeutic regimens based on recent molecular and genomic discoveries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.